B. Braun Australia Supports Healthcare System During National IV Fluids Shortage
Although its supply chain remains unaffected, the Company recognises the growing need across the country and acted swiftly to secure additional stock of intravenous (IV) fluids.
B. Braun Addresses IV Fluid Shortage Amidst Growing Concerns
Recognizing the critical nature of this shortage, we are actively exploring solutions and engaging with the Therapeutic Goods Administration (TGA) to address the situation. Our commitment remains steadfast in ensuring a consistent supply of products to our existing clients.
B. Braun drives innovation in health care while
sales and profit improved
The B. Braun Group grew its business operations and successfully advanced its strategy in the 2023 fiscal year. Sales rose 3.0 percent to 8.8 billion euros (previous year: 8.5 billion euros) and profit before tax grew 15.3 percent.
If you are a journalist and have questions about B. Braun or need any material which you cannot find in our newsroom, you are welcome to get in contact with us.
